Literature DB >> 18853832

Does a delay in performing an activated clotting (ACT) test really matter? A study in nonheparinized blood and a single ACT machine.

Bridget M Philip1, John G Brock-Utne, Harry J M Lemmens, Richard A Jaffe, Paul E Shuttleworth.   

Abstract

Activating clotting time (ACT) is a point-of-care, blood clotting test used to monitor anticoagulation. Recently, institutional requirements have required that ACT testing be completed outside the operating room with trained, certified personnel other than anesthesia staff. For this reason, in this study, we looked at whether a delay in processing an ACT makes a significant difference to the ACT results. Twenty patients between 18 and 65 years of age consented to the study, each undergoing non-cardiac surgery, with no intraoperative administration of heparin. The study was approved by our Institutional Review Board. A blood sample was taken from the patient's arterial line in the operating room. Immediately afterward, 1 mL was placed into each of two ACT cartridges and the measurement was done in a Medtronic ACT2 machine. The first ACT value was 126.9 +/- 14.5 seconds. The ACT value at approximately 30 minutes was 108.3 +/- 20.3 seconds (p < .0001). The time between the first and last measurements was 29.4 +/- 3.0 minutes. The results suggest that the ACT values decrease over time between sampling all measurements. At approximately 30 minutes, the ACT values average 15% less than the control measurements. Therefore, it would seem prudent to determine ACT values immediately in the operating room without any delay, using point-of-care testing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18853832      PMCID: PMC4680646     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  6 in total

1.  How does the age of a blood sample affect it's activated clotting time? Comparison of eight different devices.

Authors:  Bruce Searles; Fadi Nasrallah; Edward Darling; Sarah Yarcusko
Journal:  J Extra Corpor Technol       Date:  2002-09

2.  The in vitro effects of aprotinin on twelve different ACT tests.

Authors:  Karen Jones; Fadi Nasrallah; Edward Darling; Nicole Clay; Bruce Searles
Journal:  J Extra Corpor Technol       Date:  2004-03

3.  Activated coagulation time of whole blood.

Authors:  P G Hattersley
Journal:  JAMA       Date:  1966-05-02       Impact factor: 56.272

4.  The effect of temperature and aprotinin during cardiopulmonary bypass on three different methods of activated clotting time measurement.

Authors:  David Machin; Philip Devine
Journal:  J Extra Corpor Technol       Date:  2005-09

Review 5.  Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.

Authors:  J Hirsh; T E Warkentin; R Raschke; C Granger; E M Ohman; J E Dalen
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

6.  Point-of-care and standard laboratory coagulation testing during cardiovascular surgery: balancing reliability and timeliness.

Authors:  J C Fitch; G P Mirto; K L Geary; D W Byrne; R L Hines
Journal:  J Clin Monit Comput       Date:  1999-05       Impact factor: 2.502

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.